Amgen (AMGN) EBT Margin (2009 - 2026)
Amgen's quarterly EBT Margin came in at 24.18% in Q1 2026, down 3.0% year-on-year from 24.93% in Q1 2025, and up 57.58% quarter-over-quarter from 15.35% in Q4 2025.
Amgen has reported EBT Margin for 18 years, with the latest figure at 24.18% in Q1 2026.
- For the quarter ending Q1 2026, EBT Margin fell 3.0% year-over-year to 24.18%; the trailing twelve-month figure through Mar 2026 stood at 24.41% (up 493.0% YoY), and the FY2025 full-year result was 24.42%, up 1063.0% from the prior year.
- EBT Margin for Q1 2026 stood at 24.18%, up from 15.35% in the prior quarter.
- The five-year high for EBT Margin was 380.83% in Q4 2022, with the low at 0.91% in Q1 2024.
- Average EBT Margin over 5 years is 44.73%, with a median of 24.18% recorded in 2026.
- Year-over-year, EBT Margin soared 34970 bps in 2022 and sank 37043 bps in 2023.
- Tracing AMGN's EBT Margin over 5 years: stood at 380.83% in 2022, then tumbled by 97 bps to 10.4% in 2023, then fell by 17 bps to 8.61% in 2024, then jumped by 78 bps to 15.35% in 2025, then surged by 58 bps to 24.18% in 2026.
- The last three EBT Margin figures came in at 24.18% (Q1 2026), 15.35% (Q4 2025), and 41.03% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 44.70% |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 24.89% |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 6.93% |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | -21.49% |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 24.18% |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 37.07% |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | 135.53% |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 28.20% |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 24.18% |
| Dec 31, 2025 | 15.35% |
| Sep 30, 2025 | 41.03% |
| Jun 30, 2025 | 17.08% |
| Mar 31, 2025 | 24.21% |
| Dec 31, 2024 | 8.61% |
| Sep 30, 2024 | 36.47% |
| Jun 30, 2024 | 9.47% |
| Mar 31, 2024 | -0.91% |
| Dec 31, 2023 | 10.40% |
| Sep 30, 2023 | 28.21% |
| Jun 30, 2023 | 23.10% |
| Mar 31, 2023 | 56.38% |
| Dec 31, 2022 | 380.83% |
| Sep 30, 2022 | 35.96% |
| Jun 30, 2022 | 23.22% |
| Mar 31, 2022 | 26.85% |
| Dec 31, 2021 | 31.13% |
| Sep 30, 2021 | 32.14% |
| Jun 30, 2021 | 8.55% |
| Mar 31, 2021 | 31.47% |
| Dec 31, 2020 | 29.63% |
| Sep 30, 2020 | 34.35% |
| Jun 30, 2020 | 32.71% |
| Mar 31, 2020 | 32.79% |
| Dec 31, 2019 | 33.72% |
| Sep 30, 2019 | 41.68% |
| Jun 30, 2019 | 46.00% |
| Mar 31, 2019 | 43.78% |
| Dec 31, 2018 | 36.41% |
| Sep 30, 2018 | 38.00% |
| Jun 30, 2018 | 46.61% |
| Mar 31, 2018 | 49.02% |
| Dec 31, 2017 | 39.76% |
| Sep 30, 2017 | 43.66% |
| Jun 30, 2017 | 45.60% |
| Mar 31, 2017 | 47.32% |
| Dec 31, 2016 | 40.31% |
| Sep 30, 2016 | 43.84% |
| Jun 30, 2016 | 40.26% |
| Mar 31, 2016 | 43.10% |
| Dec 31, 2015 | 35.90% |
| Sep 30, 2015 | 39.74% |
| Jun 30, 2015 | 38.22% |
| Mar 31, 2015 | 38.49% |
| Dec 31, 2014 | 24.86% |
| Sep 30, 2014 | 27.58% |
| Jun 30, 2014 | 35.52% |
| Mar 31, 2014 | 27.64% |
| Dec 31, 2013 | 21.13% |
| Sep 30, 2013 | 32.34% |
| Jun 30, 2013 | 30.58% |
| Mar 31, 2013 | 32.35% |
| Dec 31, 2012 | 21.28% |
| Sep 30, 2012 | 30.06% |
| Jun 30, 2012 | 34.69% |
| Mar 31, 2012 | 35.02% |
| Dec 31, 2011 | 26.90% |
| Sep 30, 2011 | 11.71% |
| Jun 30, 2011 | 34.40% |
| Mar 31, 2011 | 36.10% |
| Dec 31, 2010 | 26.57% |
| Sep 30, 2010 | 38.15% |
| Jun 30, 2010 | 40.52% |
| Mar 31, 2010 | 40.25% |
| Dec 31, 2009 | 28.72% |
| Sep 30, 2009 | 41.22% |
| Jun 30, 2009 | 37.34% |
| Mar 31, 2009 | 38.05% |